Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML

Sponsor
The First Affiliated Hospital of Xiamen University
Study ID
NCT05305859
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Leukemia, Myeloid, Acute
  • Refractory Leukemia
  • Relapsed Adult AML

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to evaluate the safety and efficacy of Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of relapsed and/or refractory AML

Key Dates

Start date
Jan 12, 2022
Status verified
Sep 2025
Primary completion
Jan 31, 2026
Completion
Jun 30, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: venetoclax combining chidamide and azacitidine (VCA)
    28 days per cycle × at least 2 cycles； 1\) chidamide 30mg biw × 2weeks；2) venetoclax 200mg/d × 2 weeks 3) azacitidine 100mg/d d1-7

Primary Outcome Measure

Complete remission (CR) rate [ Time Frame: 2 months ]

Central Contacts

Related Studies